Quebec To List Enoxaparin Biosimilar As Valeo Pharma Prepares Launch

Canadian Firm Plans Launch During First Half Of 2020

 
• By Dean Rudge

Canada’s Valeo Pharma says it intends to pursue discussions for the inclusion of its Redesca enoxaparin biosimilar on all other provincial formularies, after being backed for listing on the Quebec public health plan.

Canadian flag waving_567680776_1200
Valeo intends to pursue discussions for the inclusion of Redesca on all other provincial formularies • Source: Shutterstock

More from Biosimilars

More from Products